Literature DB >> 33245720

Evaluating Six Commercially Available Closed-System Drug-Transfer Devices Against NIOSH's 2015 Draft Vapor Protocol.

Shiraz Halloush1,2, Ivan A Reveles3, Jim Koeller1,2.   

Abstract

Purpose: In 2015, the National Institute for Occupational Safety and Health (NIOSH) published a draft vapor containment protocol to quantitatively evaluate combined liquid, aerosol, and vapor containment performance of commercially available closed-system drug-transfer devices (CSTDs) that claim to be effective for gas/vapor containment within a controlled test environment. Until the release of this proposed protocol, no standard method for evaluating airtightness of CSTDs existed. The aim of this study was to evaluate six commercially available CSTDs utilizing NIOSH draft protocol methodology to evaluate vapor containment under a robust vapor challenge.
Methods: In this study, six commercially available CSTDs were tested utilizing draft NIOSH vapor containment protocol methodology to simulate drug compounding and administration using 70% isopropyl alcohol (IPA) as the challenge agent. All device manipulations were carried out in an enclosed test chamber. A Miran sapphIRe gas analyzer was used to detect IPA vapor levels that escaped the device. Study test included the two tasks designated by the NIOSH protocol, with additional steps added to the evaluation. Tasks were repeated 10 times for each device.
Results: Only three of the six tested CSTDs (Equashield®, HALO®, and PhaSealTM) had an average IPA vapor release below the quantifiable performance threshold (1.0 ppm) for all tasks performed. This value was selected by NIOSH to represent the performance threshold for successful containment. The remaining three CSTDs had vapor release above 1 ppm at various times during the IPA manipulation process.
Conclusion: Equashield®, HALO®, and PhaSealTM devices tested met the 2015 NIOSH protocol quantifiable performance threshold, functioning as a truly closed system. Quantifiable effective data may be useful in product selection.
© The Author(s) 2019.

Entities:  

Keywords:  CSTD; NIOSH; hazardous drugs; health care workers; occupational exposure; vapor release

Year:  2019        PMID: 33245720      PMCID: PMC7672663          DOI: 10.1177/0018578719848730

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  34 in total

1.  Using a closed-system protective device to reduce personnel exposure to antineoplastic agents.

Authors:  Catherine Wick; Matthew H Slawson; James A Jorgenson; Linda S Tyler
Journal:  Am J Health Syst Pharm       Date:  2003-11-15       Impact factor: 2.637

2.  Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers.

Authors:  Thomas H Connor; D Gayle DeBord; Jack R Pretty; Marc S Oliver; Tracy S Roth; Peter S J Lees; Edward F Krieg; Bonnie Rogers; Carmen P Escalante; Christine A Toennis; John C Clark; Belinda C Johnson; Melissa A McDiarmid
Journal:  J Occup Environ Med       Date:  2010-10       Impact factor: 2.162

3.  Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device.

Authors:  Paul J M Sessink; Thomas H Connor; James A Jorgenson; Timothy G Tyler
Journal:  J Oncol Pharm Pract       Date:  2010-02-15       Impact factor: 1.809

4.  Application of the 2015 proposed NIOSH vapor containment performance protocol for closed system transfer devices used during pharmacy compounding and administration of hazardous drugs.

Authors:  Charlotte M Forshay; Shawn O Streeter; Stephanie A Salch; Stephen F Eckel
Journal:  J Oncol Pharm Pract       Date:  2018-07-24       Impact factor: 1.809

5.  Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan.

Authors:  Jin Yoshida; Shigeki Koda; Shozo Nishida; Toshiaki Yoshida; Keiko Miyajima; Shinji Kumagai
Journal:  J Oncol Pharm Pract       Date:  2010-08-10       Impact factor: 1.809

6.  Cyclophosphamide contamination observed on the external surfaces of drug vials and the efficacy of cleaning on vial contamination.

Authors:  Karine Touzin; Jean-François Bussières; Eric Langlois; Michel Lefebvre; Claude Gallant
Journal:  Ann Occup Hyg       Date:  2008-07-28

7.  Reduction in Surface Contamination With Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation of a Closed-System Drug Transfer Device.

Authors:  Paul J M Sessink; Jason Trahan; Joseph W Coyne
Journal:  Hosp Pharm       Date:  2013-03

8.  Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital.

Authors:  M Hedmer; H Tinnerberg; A Axmon; B A G Jönsson
Journal:  Int Arch Occup Environ Health       Date:  2007-12-08       Impact factor: 3.015

9.  Contamination of syringe plungers during the sampling of cyclophosphamide solutions.

Authors:  Bertrand Favier; Laurence Gilles; Jean François Latour; Michel Desage; Francesco Giammarile
Journal:  J Oncol Pharm Pract       Date:  2005-03       Impact factor: 1.809

10.  Occupational Exposure to Antineoplastic Drugs: Identification of Job Categories Potentially Exposed throughout the Hospital Medication System.

Authors:  Chun-Yip Hon; Kay Teschke; Prescillia Chua; Scott Venners; Lynne Nakashima
Journal:  Saf Health Work       Date:  2011-09-30
View more
  2 in total

1.  Source apportionment and quantification of liquid and headspace leaks from closed system drug-transfer devices via Selected Ion Flow Tube Mass Spectrometry (SIFT-MS).

Authors:  Amos Doepke; Robert P Streicher
Journal:  PLoS One       Date:  2021-11-04       Impact factor: 3.240

2.  Evaluation of three barrier-type closed system transfer devices using the 2015 NIOSH vapor containment performance draft protocol.

Authors:  Andrew Szkiladz; Shawn Hegner
Journal:  Drugs Ther Perspect       Date:  2022-03-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.